Patents by Inventor Beiyao Zheng

Beiyao Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING A SUBJECT HAVING MULTIPLE SYSTEM ATROPHY
    Publication number: 20230372318
    Abstract: Disclosed are methods for treating a subject having multiple system atrophy (MSA) using ampreloxetine or a pharmaceutically acceptable salt thereof. The methods disclosed include using ampreloxetine or a pharmaceutically acceptable salt thereof to (i) treat the symptoms of neurogenic orthostatic hypotension in a subject having MSA; (ii) reduce the magnitude of decline in the quality of life a subject having MSA; and/or (iii) increase the level of norepinephrine in a subject having MSA.
    Type: Application
    Filed: March 28, 2023
    Publication date: November 23, 2023
    Inventors: Ross VICKERY, David L. Bourdet, Tadhg Guerin, Lucy Norcliffe-Kaufmann, Beiyao Zheng
  • ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20220162332
    Abstract: The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: September 10, 2021
    Publication date: May 26, 2022
    Inventors: Rachel Humphrey, Lori Carman, Matthias Will, Beiyao Zheng, Kathe Balinski
  • Activatable anti-PDL1 antibodies, and methods of use thereof
    Patent number: 11168144
    Abstract: The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: November 9, 2021
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Rachel Humphrey, Lori Carman, Matthias Will, Beiyao Zheng, Kathe Balinski
  • ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20190016814
    Abstract: The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 31, 2018
    Publication date: January 17, 2019
    Applicant: CytomX Therapeutics, Inc.
    Inventors: Rachel Humphrey, Lori Carman, Matthias Will, Beiyao Zheng, Kathe Balinski